Lexaria Bioscience Corp. (LEXX) Earnings History
Annual and quarterly earnings data from 2006 to 2025
Loading earnings history...
LEXX EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
LEXX Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | 83.2% | -1648.0% | -1686.0% |
| 2024 | 82.6% | -1226.7% | -1248.2% |
| 2023 | 23.9% | -2888.5% | -2946.4% |
| 2022 | 18.3% | -2545.4% | -2846.3% |
| 2021 | 75.7% | -763.8% | -557.2% |
Download Data
Export LEXX earnings history in CSV or JSON format
Free sign-in required to download data
Lexaria Bioscience Corp. (LEXX) Earnings Overview
As of May 8, 2026, Lexaria Bioscience Corp. (LEXX) reported trailing twelve-month net income of -$11M, reflecting -40.4% year-over-year growth. The company earned $-0.50 per diluted share over the past four quarters, with a net profit margin of -1686.0%.
Looking at the long-term picture, LEXX's historical earnings data spans multiple years. The company achieved its highest annual net income of -$251,508 in fiscal 2012.
Lexaria Bioscience Corp. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including ATAI (-$154M net income, -48464.0% margin), CMPS (-$288M net income), MNMD (-$238M net income), LEXX has outperformed on profitability metrics. Compare LEXX vs ATAI →
LEXX Earnings vs Peers
Earnings metrics vs comparable public companies
LEXX Historical Earnings Data (2006–2025)
20 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$12M | -105.4% | -$12M | $-0.66 | -1686.0% | -1648.0% |
| 2024 | -$6M | +13.0% | -$6M | $-0.47 | -1248.2% | -1226.7% |
| 2023 | -$7M | +8.3% | -$7M | $-1.01 | -2946.4% | -2888.5% |
| 2022 | -$7M | -80.5% | -$7M | $-1.24 | -2846.3% | -2545.4% |
| 2021 | -$4M | -2.4% | -$6M | $-0.92 | -557.2% | -763.8% |
| 2020 | -$4M | +4.0% | -$4M | $-1.42 | -1249.7% | -1311.6% |
| 2019 | -$4M | +37.9% | -$4M | $-1.62 | -1841.5% | -1860.6% |
| 2018 | -$7M | -253.0% | -$7M | $-2.79 | -1523.0% | -1526.3% |
| 2017 | -$2M | -53.9% | -$2M | $-0.95 | -2937.3% | -3022.4% |
| 2016 | -$1M | +31.4% | -$1M | $-0.83 | -2983.4% | -3093.5% |
See LEXX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs LEXX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare LEXX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonLEXX — Frequently Asked Questions
Quick answers to the most common questions about buying LEXX stock.
Is LEXX growing earnings?
LEXX EPS fell to $-0.50, with earnings declining -40.4%. This contrasts with the 5-year CAGR of N/A. TTM net income dropped to $-11M.
What are LEXX's profit margins?
Lexaria Bioscience Corp. net margin is -1686.0%, with operating margin at -1648.0%. Below-average margins reflect competitive or cost pressures.
How consistent are LEXX's earnings?
LEXX earnings data spans 2006-2025. The declining earnings trend is -40.4% YoY. Historical data enables comparison across business cycles.